Evidence map›Paper›PMID 38927950›Full record

ArticleCancers2024

Development of Traceable Mouse Models of Advanced and Metastatic Bladder Cancer.

Emma Desponds, Konstantina Kioseoglou, Hana Zdimerova, Marco Ongaro, Grégory Verdeil, Marine M Leblond

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emma DespondsDepartment of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, 1015 Lausanne, Switzerland.
Konstantina KioseoglouDepartment of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, 1015 Lausanne, Switzerland.
Hana ZdimerovaDepartment of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, 1015 Lausanne, Switzerland.
Marco OngaroDepartment of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, 1015 Lausanne, Switzerland.
Grégory VerdeilDepartment of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, 1015 Lausanne, Switzerland.ORCID 0000-0001-9445-8474
Marine M LeblondDepartment of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, 1015 Lausanne, Switzerland.ORCID 0009-0007-6919-2855

Funding

ISREC foundation Grantswiss cancer research foundation KFS-4840-08-2019-RSwiss National Science Foundation 310030_215153
6 · The paper itself

Abstract

Bladder cancer (BC) is the fourth most common cancer in men, with a poor patient prognosis for advanced disease. The poor survival of patients with muscle-invasive bladder cancer (MIBC) and metastatic status emphasizes the urgent need to develop new therapies. Lacking in the field of BC is the availability of relevant advanced BC mouse models, especially metastatic ones, that accurately recapitulate the complexities of human pathology to test and study new therapeutic strategies. Addressing this need, we developed a traceable mouse model of BC that expresses tumor-associated antigens within the context of advanced muscle-invasive BC. This novel system was achieved through the deletion of the

Indexed as

bladder cancermetastasismouse model

Identifiers

PMID38927950
PMCPMC11202260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.